Hypertrophic Cardiomyopathy Genetic Test: MYH7, MYBPC3, and Results

A hypertrophic cardiomyopathy genetic test looks for inherited DNA changes that can cause abnormal thickening of the heart muscle. MYBPC3 and MYH7 are the most frequently identified sarcomere genes, but modern panels also examine other well-supported genes and conditions that can mimic hypertrophic cardiomyopathy. Genetic testing does not replace an echocardiogram, electrocardiogram, cardiac MRI, or clinical evaluation. Instead, it can explain why hypertrophic cardiomyopathy developed and make family screening more precise. A pathogenic or likely pathogenic variant may allow relatives who did not inherit it to stop repeated cardiology surveillance, while relatives who did inherit it can begin age-appropriate monitoring before symptoms appear. Results require careful interpretation because incomplete penetrance is common, disease severity varies widely, and a variant of uncertain significance should not be treated as a diagnosis. The most useful testing starts with the family member who clearly has hypertrophic cardiomyopathy and includes genetic counseling before and after the result.

• A positive pathogenic or likely pathogenic result can confirm an inherited cause, but it does not predict exactly when symptoms will begin or how severe disease will become.
• MYBPC3 and MYH7 account for a large share of identifiable sarcomeric HCM, yet many clinically diagnosed patients have no currently detectable causal variant.
• A negative genetic test does not rule out hypertrophic cardiomyopathy and does not replace heart screening for relatives when no familial variant is known.
• A variant of uncertain significance should not guide predictive testing, sports restrictions, medication, or implantable-defibrillator decisions by itself.
• First-degree relatives of a person with HCM usually need ECG and cardiac imaging unless a known familial pathogenic variant has been excluded.
• Chest pain, fainting during exertion, sustained palpitations, or sudden collapse requires prompt medical evaluation regardless of genetic test status.

Table of Contents

• What the HCM genetic test examines
• Who benefits from testing
• How the test is done
• Understanding positive, negative, and uncertain results
• Family screening after genetic testing
• How genetics affects treatment and risk assessment
• Children, pregnancy, exercise, and reproductive planning
• Using the result well over time

What the HCM genetic test examines

Hypertrophic cardiomyopathy, or HCM, is defined by increased left ventricular wall thickness that is not fully explained by another cause such as longstanding high blood pressure, aortic valve stenosis, or intense athletic training. In adults, unexplained maximal wall thickness of 15 mm or more generally supports the diagnosis. A threshold of 13 to 14 mm can be meaningful in a person with a family history or known familial pathogenic variant. Children are assessed with measurements adjusted for body size.

The genetic test examines genes that influence the heart’s contractile machinery, energy handling, structure, and storage pathways. Most inherited nonsyndromic HCM involves proteins in the sarcomere, the microscopic unit that allows heart muscle cells to contract.

The two most commonly implicated genes are:

• MYBPC3, which makes cardiac myosin-binding protein C. Many pathogenic variants reduce the amount of functional protein. Disease may appear later in life, but timing varies greatly.
• MYH7, which makes beta-myosin heavy chain, a major motor protein in heart muscle. Many pathogenic variants alter the protein’s function rather than eliminating it.

Other established sarcomere genes include TNNT2, TNNI3, TPM1, ACTC1, MYL2, MYL3, and TNNC1. Panels may also include genes associated with syndromic or metabolic conditions that cause left ventricular thickening, such as GLA in Fabry disease, LAMP2 in Danon disease, PRKAG2 in glycogen-storage cardiomyopathy, and TTR in transthyretin amyloidosis.

Including phenocopy genes matters because some mimics have treatments and surveillance needs that differ sharply from sarcomeric HCM. For example, Fabry disease can affect the kidneys and nervous system, while Danon disease may progress rapidly and include skeletal muscle or cognitive features.

Panel size should reflect evidence. A very broad panel can increase the chance of uncertain findings in genes with weak or disputed links to HCM. ClinGen’s recent reappraisal found that some historically included genes lacked enough evidence for routine causal interpretation. A high-quality cardiovascular genetic panel should clearly state which genes have definitive, strong, or moderate disease validity and how technically difficult regions are covered.

The test usually detects single-nucleotide variants and small insertions or deletions. Many laboratories also assess larger deletions and duplications. Some cases may require mitochondrial testing, repeat-expansion analysis, RNA studies, or genome sequencing, depending on the phenotype and initial results.

Who benefits from testing

Genetic testing is recommended or strongly considered for a person with a clinical diagnosis of HCM when the result can clarify the cause or support family screening. Testing should usually begin with the most clearly affected living relative, called the proband. Starting with an unaffected relative reduces the chance of obtaining a meaningful answer because a negative result cannot show which familial variant to look for.

Testing may be particularly informative when HCM:

• Appears at a young age
• Occurs in more than one relative
• Is associated with unexplained sudden cardiac death in the family
• Produces marked wall thickening without another adequate explanation
• Coexists with conduction disease, skeletal muscle weakness, neuropathy, kidney disease, hearing loss, developmental differences, or unusual laboratory findings
• Has imaging or ECG features suggesting a specific genetic cause

A three-generation family history should include cardiomyopathy, heart failure, atrial fibrillation, pacemakers, implantable cardioverter-defibrillators, heart transplant, unexplained drowning, single-vehicle crashes, seizures with exertion, and sudden death. Family labels such as “enlarged heart” or “heart attack” may hide an inherited cardiomyopathy.

Genetic testing can still be useful in an apparently isolated case. Parents may have mild, late-onset, or unrecognized disease. A variant may have arisen de novo in the affected person. Family size may be small, or relatives may have died before modern imaging became available.

Testing is not required to make a clinical HCM diagnosis. A person with clear imaging findings should receive appropriate evaluation and treatment even if genetic testing is declined, unavailable, or negative. Conversely, a positive genetic result in someone without hypertrophy identifies genetic susceptibility, often called genotype-positive/phenotype-negative status; it does not mean the person currently has clinical HCM.

Postmortem genetic testing may be considered after sudden unexplained death, especially in a young person. The yield depends on the available tissue, the quality of the clinical information, and whether the autopsy showed cardiomyopathy. Results should be coordinated with a cardiovascular genetics team because interpretation can affect many relatives.

How the test is done

HCM genetic testing usually requires a blood or saliva sample. No fasting is needed, and heart medicines do not alter the DNA result. Blood can provide a more reliable DNA quantity in some situations, but both sample types are widely used.

Before ordering, the clinician or genetic counselor should review:

• Echocardiogram and cardiac MRI measurements
• ECG and ambulatory rhythm-monitoring results
• Exercise symptoms and blood-pressure response
• Other causes of left ventricular hypertrophy
• The age and medical details of affected relatives
• The laboratory’s gene list and technical methods
• Possible insurance, privacy, and family implications

Testing often takes several weeks. The laboratory compares detected variants with population databases, published cases, functional studies, family segregation, and established rules for variant classification. The report may list one or more findings as pathogenic, likely pathogenic, uncertain, likely benign, or benign.

The test’s diagnostic yield is highest in people with familial disease and classic sarcomeric features. It is lower in older adults with mild hypertrophy, substantial hypertension, or no family history. Across clinical cohorts, a disease-causing variant is often found in roughly 30% to 60% of patients, depending on how patients were selected and which genes were counted.

Testing should be paired with informed consent. A result may reveal risk to children and siblings, uncover unexpected biological relationships, or create uncertainty that lasts for years. In some countries, genetic information has legal protections for health insurance or employment but not for life, disability, or long-term-care insurance. Local rules should be reviewed before testing when these concerns are important.

Consumer health tests are not a substitute for clinical HCM testing. They may examine only a few variants, omit rare family-specific changes, and use interpretation methods not designed for medical diagnosis. Any potentially important consumer result should be confirmed in a certified clinical laboratory before it affects care.

Understanding positive, negative, and uncertain results

The result category determines what can safely be done with the information.

Result	Meaning for the tested person	Meaning for relatives
Pathogenic or likely pathogenic	Supports a molecular diagnosis when the gene and phenotype fit.	Targeted testing can identify relatives who inherited or did not inherit the familial variant.
Negative	No reportable causal variant was found; clinical HCM remains valid if imaging criteria are met.	Relatives usually continue clinical screening because there is no variant that can rule inherited risk in or out.
Variant of uncertain significance	The evidence is insufficient to call the variant disease-causing or benign.	Predictive testing of unaffected relatives is generally inappropriate; selected segregation studies may help the laboratory interpret it.
Benign or likely benign	The finding is not considered the cause of HCM.	It should not be used for cascade testing or surveillance decisions.

A positive result does not forecast a fixed future. Penetrance is age-dependent and incomplete: some carriers never develop measurable hypertrophy, while others develop disease in childhood or later adulthood. Expression is variable even among relatives with the same variant. One person may remain asymptomatic; another may develop obstruction, atrial fibrillation, heart failure, or ventricular arrhythmia.

Gene and variant information can sometimes add context. MYH7-related disease may appear earlier on average in some cohorts, while many MYBPC3 loss-of-function variants show later and highly variable onset. These are population tendencies, not reliable individual predictions. A person’s imaging, symptoms, rhythm history, fibrosis, family history, and changes over time remain more useful for near-term care.

A negative result may reflect a causal variant outside current knowledge, a variant type the assay cannot detect, a polygenic contribution, or a nongenetic cause. The report should be reviewed for coverage limits. Broader sequencing or reanalysis may be appropriate when onset is very early, extracardiac features suggest a syndrome, or the family pattern remains compelling.

A VUS must not be promoted to a diagnosis because it appears rare or because a computer predicts damage. Proper classification requires multiple evidence types. The report should be revisited periodically because laboratories may reclassify variants as new family and population data emerge. The general rules for positive, negative, and uncertain genetic results are especially important in HCM, where an incorrect interpretation can lead to unnecessary lifelong cardiac surveillance or false reassurance.

Family screening after genetic testing

Family screening combines genetic testing with cardiology evaluation. The path depends on whether a pathogenic familial variant was found.

When a pathogenic or likely pathogenic variant is identified, first-degree relatives can receive targeted testing for that exact variant. A relative who tests positive usually enters periodic clinical surveillance, even with a normal current echocardiogram. A relative who tests negative for the known familial variant can generally be released from HCM-specific serial screening, provided the family has a single well-established cause and no independent clinical concern.

When the proband’s test is negative or shows only a VUS, genetic testing cannot clear relatives. First-degree relatives usually need ECG and echocardiography at intervals based on age, symptoms, family history, and guideline recommendations. Cardiac MRI may be added when echocardiographic images are limited or diagnostic uncertainty remains.

Children and adolescents often need more frequent screening because growth, puberty, and sports participation can reveal disease. Adults may be screened every few years when prior studies are normal, but the interval becomes shorter if symptoms, borderline findings, or a malignant family history appear. Screening schedules should be individualized rather than copied from a single age table.

Relatives should seek earlier evaluation for exertional fainting, chest pain, breathlessness out of proportion to activity, sustained palpitations, or reduced exercise capacity. A normal study several years ago does not exclude later-onset HCM.

Family communication works best when the proband shares a copy of the laboratory report, not just the gene name. Targeted testing requires the exact variant notation and the original laboratory classification. A family letter from the genetics clinic can explain who is at risk and how to arrange testing without disclosing unnecessary personal details.

How genetics affects treatment and risk assessment

Genetic testing currently influences family screening more directly than day-to-day treatment. HCM management is based mainly on symptoms, obstruction, rhythm findings, ventricular function, and sudden-death risk markers.

Clinical care may include:

• Beta blockers, nondihydropyridine calcium-channel blockers, or disopyramide for symptoms and outflow obstruction
• Cardiac myosin inhibitors for selected adults with symptomatic obstructive HCM under specialist monitoring
• Septal myectomy or alcohol septal ablation when severe obstruction persists despite medication
• Anticoagulation for HCM-associated atrial fibrillation according to guideline recommendations
• Implantable cardioverter-defibrillator placement for selected people at meaningful risk of sudden cardiac death
• Heart-failure treatment and transplant evaluation in advanced disease

A pathogenic variant alone is usually not enough to justify an implantable defibrillator. Risk assessment examines previous cardiac arrest or sustained ventricular tachycardia, unexplained syncope, family history of HCM-related sudden death, maximal wall thickness, apical aneurysm, reduced ejection fraction, nonsustained ventricular tachycardia, and the extent of late gadolinium enhancement on cardiac MRI. Different guidelines combine these factors in different ways.

Genotype may refine prognosis in groups. Sarcomere-positive patients often develop disease younger and may have a greater lifetime burden than genotype-negative patients with similar initial hypertrophy. People with multiple pathogenic variants may have more severe disease. These observations support attentive follow-up but still do not replace individualized clinical risk assessment.

The genetic diagnosis can directly alter care when the result identifies a phenocopy. Enzyme replacement or chaperone therapy may be relevant in Fabry disease; transthyretin-directed therapies may apply to amyloidosis; metabolic and conduction-system surveillance differs in PRKAG2 and Danon disease. This is one reason panels should include carefully selected mimic genes.

Children, pregnancy, exercise, and reproductive planning

Children with a familial pathogenic variant need age-appropriate cardiology care. Testing minors is generally considered reasonable because the result can change medical surveillance and sports evaluation. A positive result does not automatically mean a child must avoid all exercise. Most children benefit from ordinary physical activity, while competitive or high-intensity participation should be discussed through shared decision-making with an HCM specialist.

Exercise advice has shifted away from universal prohibition. Recreational moderate-intensity activity is encouraged for many people with HCM. Competitive sports may be possible for selected individuals after comprehensive evaluation and informed discussion of uncertainty. New symptoms should prompt reassessment.

Pregnancy is often tolerated in women with stable HCM, but preconception review is important. The team assesses obstruction, symptoms, ventricular function, arrhythmias, medications, and anticoagulation needs. Some medicines require adjustment before conception. Each child of a person with an autosomal dominant pathogenic variant generally has a 50% chance of inheriting it.

Reproductive options include natural conception with postnatal testing, prenatal diagnosis through chorionic villus sampling or amniocentesis, and in vitro fertilization with preimplantation genetic testing for monogenic disease. These options require a known familial pathogenic variant; a VUS should not be used for embryo selection or definitive prenatal diagnosis.

The choice is personal. HCM severity cannot be predicted precisely from inheritance alone, and many variant carriers live full lives with appropriate monitoring. Genetic counseling should present options without directing families toward a particular reproductive decision.

Genotype-positive, phenotype-negative follow-up

A relative who carries the familial pathogenic variant but has no left ventricular hypertrophy is often described as genotype-positive and phenotype-negative. This is a risk state, not a clinical diagnosis of HCM. The person should not be labeled as having obstruction, heart failure, or a high sudden-death risk simply because the DNA result is positive.

Current guidance recommends periodic clinical review, ECG, and cardiac imaging because hypertrophy can appear later. Typical intervals are about every one to two years for children and adolescents and every three to five years for adults, with earlier reassessment after new symptoms or a meaningful change in family history. The cardiologist may shorten the interval during rapid growth, intensive athletic training, pregnancy, or when an earlier study was borderline. Cardiac MRI is useful when echocardiography is technically limited or the diagnosis remains uncertain, but it is not automatically required at every visit.

A genotype-positive, phenotype-negative result does not by itself justify a preventive implantable defibrillator. It also does not require universal exclusion from vigorous or competitive sport. The 2024 multisociety guideline considers competitive participation reasonable in this group, provided the person has appropriate evaluation and understands the remaining uncertainty. Exercise decisions should still account for symptoms, rhythm monitoring, imaging, the family’s history, the specific sport, and access to emergency response. New exertional fainting, sustained palpitations, chest discomfort, or unexplained loss of performance should trigger prompt reassessment rather than waiting for the next scheduled visit.

Using the result well over time

A genetic report is not static. Gene-disease evidence and variant classifications change, so the ordering clinic and laboratory should have a plan for reinterpretation. Reanalysis may be especially worthwhile after several years, after a new diagnosis in a relative, or when new syndromic features appear.

Keep copies of the full report, echocardiograms, cardiac MRI summaries, and the family pedigree. Record the laboratory, report date, gene, transcript, DNA change, protein change, and classification. This information helps new clinicians avoid repeating tests or misreading a family result.

Questions worth asking include:

• Does this gene have strong evidence for causing my exact HCM phenotype?
• Is the variant pathogenic, likely pathogenic, or uncertain, and what evidence supports that classification?
• Should the laboratory test another affected relative to strengthen interpretation?
• Which relatives can have targeted testing, and who still needs ECG and imaging?
• How often should genotype-positive relatives with normal imaging be screened?
• Does the result suggest a metabolic, storage, or syndromic condition rather than sarcomeric HCM?
• When will the report be reanalyzed?

The test is most successful when it creates a clear family plan. A clinically confirmed patient should continue HCM care regardless of a negative result. A genotype-positive relative should receive surveillance without being told that severe disease is inevitable. A genotype-negative relative should be released from screening only when the familial variant is firmly established and the family’s clinical picture is consistent.

References

• 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy 2024 (Guideline)
• 2023 ESC Guidelines for the management of cardiomyopathies 2023 (Guideline)
• Genetic testing and counseling for hypertrophic cardiomyopathy: An evidence-based practice resource of the National Society of Genetic Counselors 2024 (Practice Resource)
• Genetics of hypertrophic cardiomyopathy: established and emerging implications for clinical practice 2024 (Review)
• Genes Associated With Hypertrophic Cardiomyopathy: A Reappraisal by the ClinGen Hereditary Cardiovascular Disease Gene Curation Expert Panel 2025

Disclaimer

This article provides general education and cannot diagnose hypertrophic cardiomyopathy or interpret an individual genetic variant. Testing, sports advice, family screening, pregnancy planning, and defibrillator decisions should be made with a cardiologist and genetics professional who can review the full clinical record. Fainting during exercise, sustained chest pain, severe breathlessness, or sudden collapse requires urgent medical care.